Foghorn Therapeutics elects B. Lynne Parshall as Class III Director

Foghorn Therapeutics Inc.

B. Lynne Parshall elected to Board effective Aug 16, 2022; term expires at 2023 annual meeting.
Appointed Chair of the Audit Committee.
Awarded option to purchase 32,000 shares vesting equally over three years.
Compensated per non-employee director policy; no related-party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

B. Lynne Parshall

Class III Director

FHTX · Foghorn Therapeutics Inc.

Effective: 2022-08-16
Filed: August 17, 2022, 7:59 PM ET

elected B. Lynne Parshall to the Board as a Class III Director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

B. Lynne Parshall was elected as Class III Director at Foghorn Therapeutics Inc..

Action: elected
Role: Class III Director

Exact text from the filing

elected B. Lynne Parshall to the Board as a Class III Director

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-023096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.